GSK376501 + midazolam

GSK376501 + midazolam is a **combination drug** consisting of GSK376501, a partial agonist of the peroxisome proliferator-activated receptor gamma (PPARγ), and midazolam, a short-acting benzodiazepine. GSK376501 is an investigational small molecule developed by GSK for treating type 2 diabetes and obesity, acting as a PPARγ partial agonist to modulate glucose and lipid metabolism[4][2]. Midazolam is a widely used benzodiazepine with hypnotic, sedative, anxiolytic, muscle relaxant, anticonvulsant, and amnesic properties, primarily acting as a positive allosteric modulator of the GABA-A receptor[3][5]. Clinically, midazolam is employed for procedural sedation, anesthesia, and acute agitation, and can be administered via multiple routes. The combination of these drugs likely would be relevant for drug-interaction studies or special procedural use, but is not a marketed fixed-dose combination.

Other names

midazolamGSK376501GSK-376501GSK 376501